Stefan Ryser

Director Ejecutivo en

Trellis Bioscience, Inc.

66 años

61 relaciones

Health Technology

Finance

Commercial Services

Perfil

Stefan Ryser was the founder of International Biomedicine Management Partners AG, founded in 1998, holding the title of Chief Executive Officer in 2000.
Dr. Ryser is the founder of Bear Stearns Health Innoventures Management LLC, with the title of Founding Partner from 2000 to 2009.
Current job includes President, Chief Executive Officer & Director at Trellis Bioscience, Inc. since 2013.
Former jobs include Chief Executive Officer & Director at A-CUBE, Inc., Director at Arena Pharmaceuticals, Inc., Director at Achillion Pharmaceuticals, Inc., Managing Director at Bear Stearns Asset Management, Inc., Director at Entelos, Inc., Director at Tolerx, Inc., Director at Genaissance Pharmaceuticals, Inc., Director at Cytokinetics, Inc., Director & Senior VP-Corporate Strategy at Telik, Inc. from 1998 to 2009, and Head-Research Staff at Hoffmann-La Roche, Inc. from 1989 to 1997.
Education includes undergraduate and doctorate degrees from the University of Basel.

Cargos activos de Stefan Ryser

Empresas	Cargo	Inicio
Trellis Bioscience, Inc. Trellis Bioscience, Inc. BiotechnologyHealth Technology Develops treatments for infectious diseases, cancer and oncology indications	Director Ejecutivo	01/01/2013

Todos los cargos activos de Stefan Ryser

Antiguos cargos conocidos de Stefan Ryser.

Empresas	Cargo	Fin
Telik, Inc. Telik, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and commercializing novel small molecule drugs to treat serious diseases	Director/Miembro de la Junta	01/08/2009
Bear Stearns Health Innoventures Management LLC Bear Stearns Health Innoventures Management LLC Investment ManagersFinance BSHI seeks to invest in private companies with innovative research & development in areas of biotechnology. The firm prefers to be the lead investor in companies with the following characteristics: consistency with vision based on potential to enhance productivity, quality and cost-effectiveness of health care, market segment at an inflection point, innovative product or service and a proprietary, defensible and sustainable technology platform. They also look for management excellence, manageable regulatory risks and a viable business model based on market size, demand/medical need, sustainable margins, suitability for alliances and technology-into-product feasibility.	Director de Inversiones	31/03/2009
ACHILLION PHARMACEUTICALS, INC.	Director/Miembro de la Junta	27/04/2007
International Biomedicine Management Partners AG International Biomedicine Management Partners AG Investment ManagersFinance Acts as an alternative investment manager	Fundador	01/04/2000
Hoffmann-La Roche, Inc. Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions	Corporate Officer/Principal	31/12/1997

Ver el detalle de la experiencia de Stefan Ryser.

Formación de Stefan Ryser.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Stefan Ryser.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	16
Roche Holding AG Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics	Health Technology
Bear Stearns Asset Management, Inc. Bear Stearns Asset Management, Inc. Investment ManagersFinance Bear Stearns Asset Management, Inc. is an asset management firm and broker/dealer located in New York City. The firm is a subsidiary of JPMorgan Asset Management, Inc. and their ultimate parent is JPMorgan Chase & Co., Inc. (NYSE: JPM). They manage equity and fixed-income separate accounts, mutual funds, hedge funds, private equity funds and venture capital funds. Their clients include corporations, municipal governments, multi-employer plans, endowments, foundations, family groups and high net-worth individuals	Finance
Telik, Inc. Telik, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and commercializing novel small molecule drugs to treat serious diseases	Health Technology
Genaissance Pharmaceuticals, Inc. Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and uses genetic information to diagnostic and therapeutic products	Health Technology
Arena Pharmaceuticals, Inc. Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products	Health Technology
Tolerx, Inc. Tolerx, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products	Health Technology
Cytokinetics, Inc. Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products	Health Technology
Trellis Bioscience, Inc. Trellis Bioscience, Inc. BiotechnologyHealth Technology Develops treatments for infectious diseases, cancer and oncology indications	Health Technology
Achillion Pharmaceuticals, Inc. Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases	Health Technology
Entelos, Inc. Entelos, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical trial partner that supports drug research and development teams	Commercial Services
Hoffmann-La Roche, Inc. Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions	Health Technology
Bear Stearns Health Innoventures Management LLC Bear Stearns Health Innoventures Management LLC Investment ManagersFinance BSHI seeks to invest in private companies with innovative research & development in areas of biotechnology. The firm prefers to be the lead investor in companies with the following characteristics: consistency with vision based on potential to enhance productivity, quality and cost-effectiveness of health care, market segment at an inflection point, innovative product or service and a proprietary, defensible and sustainable technology platform. They also look for management excellence, manageable regulatory risks and a viable business model based on market size, demand/medical need, sustainable margins, suitability for alliances and technology-into-product feasibility.	Finance
University of Basel University of Basel Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
International Biomedicine Management Partners AG International Biomedicine Management Partners AG Investment ManagersFinance Acts as an alternative investment manager	Finance
The European Association for Bioindustries
A-CUBE, Inc. A-CUBE, Inc. BiotechnologyHealth Technology Develops novel antibodies	Health Technology